Strategic Implications Of Trial Design In Early Phase Oncology Studies

How can pharma sponsors can successfully navigate the critically important early phase development of their oncology therapies? With 2023’s new FDA Guidance for Dosage Optimization in Oncology Treatment (known as Project Optimus) and the increasingly complex and varied oncology therapies landscape, smart trial design is essential to finding success.

Download your free article to discover:

How patient-centricity plays a critical role in early oncology trials.
Which factors matter most in formulating successful and safe dosing strategies.
How dose optimization has changed in a post-Project Optimus landscape.
What to consider when making clinical trial design decisions.
What resources are available to sponsors navigating oncology’s new trial terrain.

Sign up to our content service and access now

Your company email address

Please select your industry: (max 1)

Opt In?

By you requesting this resource, you agree to our terms of use. All data is protected by our Privacy Notice. You can change your contact preferences here. If you have any further questions please get in contact.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Caidya to store and process the information submitted to provide you the content requested. They are subject to Caidya's Privacy Policy.

Strategic Implications Of Trial Design In Early Phase Oncology Studies

Sign up to our content service and access now

Opt In?

Explore similar content

Resiliency and innovation - Navigating the current biotech landscape

HIV – Global Clinical Trial Landscape

Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations